Core Points - Movano Health has received approval from the Nasdaq Hearings Panel to continue its listing on Nasdaq, contingent upon regaining compliance with specific listing rules by set deadlines [1][2] - The company must file its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, and June 30, 2025, by September 30, 2025, and maintain a bid price of at least $1.00 per share by October 30, 2025 [1][2] - Movano Health is actively working with a new auditor to complete the necessary filings and has filed a Preliminary Proxy Statement for a reverse stock split proposal to help meet the bid price requirement [2] Company Overview - Movano Health, founded in 2018, focuses on developing healthcare solutions that provide medical-grade data through wearable devices [3] - The company's flagship product, the Evie Ring, aims to deliver personalized health insights by capturing comprehensive health data [3][4] - Movano Health's proprietary technologies are designed to proactively monitor and manage health outcomes across various patient populations [4]